The New Era of Hepatitis C Virus Therapy

被引：2

作者：

Al-Judaibi, Bandar ^{[1
,2
]}

机构：

[1] Univ Western Ontario, Dept Med, Multiorgan Transplant Unit, London, ON, Canada

[2] King Saud Univ, Dept Med, Div Gastroenterol, Riyadh, Saudi Arabia

来源：

SAUDI JOURNAL OF GASTROENTEROLOGY | 2015年 / 21卷 / 06期

关键词：

Cirrhosis and null responders; direct antiviral agents; hepatitis C virus; HCV GENOTYPE 1; DACLATASVIR PLUS SOFOSBUVIR; TREATMENT-NAIVE PATIENTS; INTERFERON-ALPHA; 2A; PEGYLATED INTERFERON; COMPENSATED CIRRHOSIS; LIVER-TRANSPLANTATION; COMBINATION THERAPY; NATURAL-HISTORY; DOUBLE-BLIND;

D O I：

10.4103/1319-3767.170947

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

The hepatitis C virus (HCV) has a significant medical and economic impact on societies around the world, and it has been estimated that 130-180 million people are infected with HCV. Therapies for HCV are currently undergoing a revolution. In recent years, several new treatments have been approved by the United States Food and Drug Administration, and many other treatments are in phase II or III clinical trials, including direct antiviral agents (DAAs). Due to recent major advances in the field of HCV therapy, a summary of findings on new HCV therapies are provided in this review article, including reports on new DAAs.

引用

页码：345 / 354

页数：10

共 73 条

[21] Optimizing treatment for HCV genotype 4: PEG-IFN alfa 2a vs. PEG-IFN alfa 2b; the debate continues [J].

Esmat, Gamal ;

El Kassas, Mohamed ;

Hassany, Mohamed ;

Gamil, Mohamed ;

El Raziky, Maissa .

LIVER INTERNATIONAL, 2014, 34 :24-28

[22]

European Commission Grants Marketing Authorization for Gilead's Harvoni®, 2015, LED SOF 1 SINGL TABL

[23] SAFETY AND EFFICACY OF TREATMENT WITH THE INTERFERON-FREE, RIBAVIRIN-FREE COMBINATION OF SOFOSBUVIR + GS-5816 FOR 12 WEEKS IN TREATMENT NAIVE PATIENTS WITH GENOTYPE 1-6 HCV INFECTION [J].

Everson, G. T. ;

Tran, T. T. ;

Towner, W. J. ;

Davis, M. N. ;

Wyles, D. ;

Nahass, R. ;

McNally, J. ;

Brainard, D. M. ;

Han, L. ;

Doehle, B. ;

Mogalian, E. ;

Symonds, W. T. ;

McHutchison, J. G. ;

Morgan, T. ;

Chung, R. T. .

JOURNAL OF HEPATOLOGY, 2014, 60 (01) :S46-S46

[24]

Fattovich G, 2002, AM J GASTROENTEROL, V97, P2886, DOI 10.1111/j.1572-0241.2002.07057.x

[25] Treatment of HCV with ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin [J].

Feld, Jordan J. ;

Kowdley, Kris V. ;

Coakley, Eoin ;

Sigal, Samuel ;

Nelson, David R. ;

Crawford, Darrell ;

Weiland, Ola ;

Aguilar, Humberto ;

Xiong, Junyuan ;

Pilot-Matias, Tami ;

DaSilva-Tillmann, Barbara ;

Larsen, Lois ;

Podsadecki, Thomas ;

Bernstein, Barry .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (17) :1594-1603

[26] STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infection [J].

Ferenci, Peter ;

Asselah, Tarik ;

Foster, Graham R. ;

Zeuzem, Stefan ;

Sarrazin, Christoph ;

Moreno, Christophe ;

Ouzan, Denis ;

Maevskaya, Marina ;

Calinas, Filipe ;

Morano, Luis E. ;

Crespo, Javier ;

Dufour, Jean-Francois ;

Bourliere, Marc ;

Agarwal, Kosh ;

Forton, Daniel ;

Schuchmann, Marcus ;

Zehnter, Elmar ;

Nishiguchi, Shuhei ;

Omata, Masao ;

Kukolj, George ;

Datsenko, Yakov ;

Garcia, Miguel ;

Scherer, Joseph ;

Quinson, Anne-Marie ;

Stern, Jerry O. .

JOURNAL OF HEPATOLOGY, 2015, 62 (06) :1246-1255

[27] The association between hepatitis C infection and survival after orthotopic liver transplantation [J].

Forman, LM ;

Lewis, JD ;

Berlin, JA ;

Feldman, HI ;

Lucey, MR .

GASTROENTEROLOGY, 2002, 122 (04) :889-896

[28] Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent [J].

Forns, Xavier ;

Gordon, Stuart C. ;

Zuckerman, Eli ;

Lawitz, Eric ;

Calleja, Jose L. ;

Hofer, Harald ;

Gilbert, Christopher ;

Palcza, John ;

Howe, Anita Y. M. ;

DiNubile, Mark J. ;

Robertson, Michael N. ;

Wahl, Janice ;

Barr, Eliav ;

Buti, Maria .

JOURNAL OF HEPATOLOGY, 2015, 63 (03) :564-572

[29] Simeprevir With Peginterferon and Ribavirin Leads to High Rates of SVR in Patients With HCV Genotype 1 Who Relapsed After Previous Therapy: A Phase 3 Trial [J].

Forns, Xavier ;

Lawitz, Eric ;

Zeuzem, Stefan ;

Gane, Ed ;

Bronowicki, Jean Pierre ;

Andreone, Pietro ;

Horban, Andrzej ;

Brown, Ashley ;

Peeters, Monika ;

Lenz, Oliver ;

Ouwerkerk-Mahadevan, Sivi ;

Scott, Jane ;

De La Rosa, Guy ;

Kalmeijer, Ronald ;

Sinha, Rekha ;

Beumont-Mauviel, Maria .

GASTROENTEROLOGY, 2014, 146 (07) :1669-+

[30]

Gane EJ, 2014, HEPATOLOGY, V60, P22

← 1 2 3 4 5 6 7 8 →